Quality by design approach implementation in media development for the production of therapeutic enzyme

Abstract

L-asparaginase is a highly demanding therapeutic enzyme. This enzyme has wide applications in food, therapeutic, and biosensor industries. Since L-asparaginase is a chemotherapeutic agent/enzyme, it is important to maintain the final product quality. Nowadays, FDA andandotherotherregulatory authorities emphasize having quality by design (QbD) based product development. Because of this requirement, QbD principles were implemented in this study for optimization of the L-asparaginase production by Bacillus subtilis THARAKA. QbD was implemented through the design of the experiment strategy. Initially, the Plackett–Burman design (PBD) was used to screen the nutrients which have a significant effect on the enzyme. Among 11 studied nutrients, 3 components glucose, L-asparagine, and (NH4)2 SO4 were screened by using PBD, and their concentrations were further optimized by using response surface methodology. Screened nutrients and process parameters were optimized using the central composite design (CCD). By sequential optimization methods such as PBD followed by CCD a 28% L-asparaginase production was enhanced.